Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Go Vida Plena vs Royal Medical Center

Go Vida Plena
Graded #151

Higher grade

vs+18.800000000000004
Royal Medical Center
Graded #492

Lower grade

The verdict

Go Vida Plena takes it — 68.2/100 to 49.4/100.

Go Vida Plena grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Go Vida Plena is a Spanish-first, Latino-focused medical weight-loss program offering GLP-1 therapy from $199/month, based in Utah.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueGo Vida Plena +32
54
22
Dose & formulationGo Vida Plena +33
75
42
Clinical oversightGo Vida Plena +21
83
62
Labs & monitoringRoyal Medical Center +23
63
86
FulfillmentGo Vida Plena +29
77
48
Contract termsEven
55
55
Go Vida Plena · left barRoyal Medical Center · right bar

The numbers

MetricGo Vida PlenaRoyal Medical Center
WeighScore68.2/10049.4/100
GradeCC
Scorecard rank#151#492
Semaglutide$199/mo (starting dose, compounded)Not disclosed
Tirzepatide$269/mo (starting dose, compounded)$450/mo (2.5 mg dose, compounded)
CoverageCoverage not publishedCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualYesInjection only
Go Vida Plena

Graded #151 · C

Strengths

  • Spanish-first, fully bilingual GLP-1 program tailored to Latino food and lifestyle - a genuinely underserved niche
  • Compounded semaglutide, tirzepatide, and oral semaglutide from $199/mo, with installment pay (Klarna, Afterpay, Affirm)
  • Free initial consultation; medications shipped discreetly to your door after a medical evaluation
  • Includes 24/7 support, 4 virtual visits a year, and ongoing nutrition coaching
  • Physician-supervised program (Utah medical backing) with continuous follow-up

Where it loses points

  • Utah-based, and the full list of states served is not published
  • Only a '$199/mo starting' price is shown upfront; tirzepatide and oral-semaglutide pricing isn't published
  • The compounding pharmacy is not named (a 'provider pharmacies' page exists but lists no name)
  • Compounded GLP-1 medications are not FDA-approved - not brand Wegovy, Ozempic, Zepbound, or Mounjaro
  • No LegitScript certification displayed
Royal Medical Center

Graded #492 · C

Strengths

  • Physician founder Dr. Dagoberto Rodriguez, MD — Emory residency, former Coral Springs Medical Center chairman, U Miami faculty
  • Tirzepatide pricing fully itemized by dose tier ($450 / $650 / $800 / $1,100) — more transparent than 'starting at' floors
  • All-inclusive pricing bundles medication, supplies, injections, lab monitoring, and physician follow-ups
  • Broad catalog (HRT, TRT, peptides, ED, hair, vitamins) reflects an established multi-program clinic
  • Florida physician with 30+ years of practice — a strong physician-led care signal

Where it loses points

  • Operating legal entity not disclosed — only the 'Royal Medical Center' brand surfaced
  • Pharmacy partner not named — buyers can't verify licensure or 503A/503B status
  • No LegitScript badge displayed
  • States served not enumerated — site says 'nationwide' with no state list
  • Headline 'starting at $116/mo' conflicts with the actual $450/mo tirzepatide floor

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard